News & Updates

Show Multimedia Only
First-line rucaparib boosts PFS in ovarian cancer regardless of HRD status First-line rucaparib boosts PFS in ovarian cancer regardless of HRD status

First-line rucaparib boosts PFS in ovarian cancer regardless of HRD status

15 Sep 2022 byRoshini Claire Anthony

First-line rucaparib maintenance therapy extends progression-free survival (PFS) in patients with ovarian, fallopian tube, or primary peritoneal cancer, according to results of the phase III ATHENA-MONO trial presented at the ESMO Gynaecological Cancers Conference 2022.

15 Sep 2022
High-dose iron infusion corrects deficiency, maintains iron stores in pregnancy

High-dose iron infusion corrects deficiency, maintains iron stores in pregnancy

12 Sep 2022 byJairia Dela Cruz

A single 1,000-mg infusion of ferric carboxymaltose (FCM) effectively resolves iron deficiency in pregnancy, preserving iron stores and reducing the need for repeat infusions as compared with the lower FCM dose, as shown in a study.

12 Sep 2022
CNS metastasis worsens survival in endometrial cancer

CNS metastasis worsens survival in endometrial cancer

12 Sep 2022

Among patients with endometrial cancer (EC), central nervous system metastasis (CNSm) is strongly associated with poor prognoses and survival outcomes, a recent study has found.

12 Sep 2022